Aplaviroc

Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist, with IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW.

Product Specifications

CAS Number

[461443-59-4]

Product Name Alternative

AK 602; GSK 873140; GW 873140

UNSPSC

12352005

Target

CCR; HIV

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Infection; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Aplaviroc.html

Solubility

10 mM in DMSO

Smiles

O=C(O)C1=CC=C(OC2=CC=C(CN(CC3)CCC3(N(CCCC)C([C@@H]([C@@H](C4CCCCC4)O)N5)=O)C5=O)C=C2)C=C1

Molecular Formula

C33H43N3O6

Molecular Weight

577.71

References & Citations

[1]Maeda K, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol. 2004 Aug;78 (16) :8654-62.|[2]Hirotomo Nakata, et al. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. Virol. 2005 Feb;79 (4) :2087-96.